Bone Loss With Exemestane: Is the Jury Still Out?
- 20 December 2005
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (36) , 9433-9434
- https://doi.org/10.1200/jco.2005.04.1376
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Precision Assessment and Radiation Safety for Dual-Energy X-Ray AbsorptiometryJournal of Clinical Densitometry, 2005
- Radiation Therapy and Tamoxifen: Concurrent or Sequential? That Is the QuestionJournal of Clinical Oncology, 2005
- Effects of the Steroidal Aromatase Inhibitor Exemestane and the Nonsteroidal Aromatase Inhibitor Letrozole on Bone and Lipid Metabolism in Ovariectomized RatsClinical Cancer Research, 2004
- Effects of steroidal and nonsteroidal aromatase inhibitors (AIs) on markers of bone turnover and lipid metabolism in healthy volunteersJournal of Clinical Oncology, 2004
- Effects of steroidal and nonsteroidal aromatase inhibitors (AIs) on markers of bone turnover and lipid metabolism in healthy volunteersJournal of Clinical Oncology, 2004
- What Is the Role of Serial Bone Mineral Density Measurements in Patient Management?Journal of Clinical Densitometry, 2002
- Precision Error of Fan-Beam Dual X-Ray Absorptiometry Scans at Spine, Hip, and ForearmJournal of Clinical Densitometry, 2000
- Long-Term Precision of DXA Scanning Assessed over Seven Years in Forty Postmenopausal WomenOsteoporosis International, 2000
- Cross-calibration, precision and patient dose measurements in preparation for clinical trials using dual energy X-ray absorptiometry of the lumbar spine.The British Journal of Radiology, 1999